Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate

Swanson JM, Seargeant JA, Taylor E, Sonuga-Barke EJS, Jensen PS, Cantwell DP: Attention deficit disorder and hyperkinetic disorder. Lancet 1998; 351:429–433

Swanson JM, Lerner M, Williams L: More frequent diagnosis of attention deficit-hyperactivity disorder (letter). N Engl J Med 1995; 333:944

Carrey NJ, Wiggins DM, Milin RP: Pharmacological treatment of psychiatric disorders in children and adolescents: focus on guidelines for the primary care practitioner. Drugs 1996; 51:750–759

Castellanos XF, Elia J, Kruesi MJ, Narsh WL, Gulotta CS, Potter WZ, Ritchie GF, Hamburger SD, Rapoport JL: Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention/hyperactivity disorder. Neuropsychopharmacology 1996; 14:125–137

Schweri MM, Skolnick P, Rafferty MF, Rice KC, Janowsky AJ, Paul SM: [3H]Threo-(+/–)-methylphenidate binding to 3,4-dihydroxyphenyl ethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem 1985; 45:1062–1070

Parran TV, Jasinski DR: Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 1991; 151:781–783

Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ: Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987; 237:1219–1223

Koob GF, Bloom FE: Cellular and molecular mechanism of drug dependence. Science 1988; 242:715–723

Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea K: Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997; 386:827–830

Greenhill LL, Abikoff HB, Arnold E, Cantwell DP, Conners CK, Elliot G, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, March J, Newcorn J, Pelham WF, Severe JB, Swanson JM, Vitiello B, Wells K: Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 34:1–10

Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor R, Hitzemann R, Logan J, Bendriem B, Gatley J, Christman D: Mapping cocaine-binding sites in human and baboon brain in vivo. Synapse 1989; 4:371–377

Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha K: Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15:213–220

Wang G-J, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G, Pascani K, Pappas N, Lu A, Cooper T, Lieberman JA: Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. European Addiction Res 1997; 3:49–54

Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer D, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR: Graphical analysis of reversible radioligand binding from time activity measurements applied to [N-11C-methyl]-(-)cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10:740–747

Logan J, Volkow ND, Fowler JS, Wang G-J, Dewey SL, MacGregor R, Schlyer D, Gatley SJ, Pappas N, King P, Hitzemman R, Vitkun S: Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 1994; 14:995–1010

Dewey SL, Smith G, Logan J, Brodie JD, Wei YD, Ferrieri RA, King P, MacGregor R, Martin PT, Wolf AP, Volkow ND, Fowler JS: GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 1992; 12:3773–3780

Ding Y-S, Sugano Y, Fowler JS, Salata C: Synthesis of the racemate and individual enantiomers of [11C]methylphenidate for studying presynaptic dopaminergic neurons with positron emission tomography. J Labeled Compounds and Radiopharmacology 1994; 34:989–997

Alexoff DL, Shea C, Fowler JS, King P, Gatley SJ, Schlyer D J, Wolf AP: Plasma input function determination for PET using a commercial laboratory robot. Nucl Med Biol 1995; 22:893–904

Volkow ND, Fowler JS, Logan J, Gatley JS, Dewey SL, MacGregor RR, Schlyer DJ, Pappas N, King P, Wolf AP: Carbon-11-cocaine binding compared at sub-pharmacological and pharmacological doses: a PET study. J Nucl Med 1995; 36:1289–1297

Wargin W, Patrick K, Kilts PC, Gualtieri CT, Ellington K, Mueller RA, Kraemer G, Breese GR: Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983; 226:382–386

Shaywitz SE, Hunt RD, Jatlow P, Cohen DJ, Young JG, Pierce RN, Anderson GM, Shaywitz BA: Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982; 69:688–694

Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha K: Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 1992; 52:561–568

Aoyama T, Kotaki H, Sasaki T, Sawada Y, Honda Y, Iga T: Nonlinear kinetics of threo-methyphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur J Pharmacol 1993; 44:79–84

Faraj GA, Israili JM, Perel ML, Jenjins ML, Holtzaman SG, Cucinell SA, Dayton PG: Metabolism and disposition of methylphenidate 14C: studies in man and animals. J Pharmacol Exp Ther 1974; 191:535–547

Oldendorf WH: Some relationships between addiction and drug delivery to the brain. NIDA Res Monogr 1992; 120:13–25

Balster RL, Schuster CR: Fixed-interval schedule of cocaine reinforcement: effects of dose and infusion duration. J Exp Anal Behav 1973; 20:119–129

Verebey K, Gold MS: From coca leaves to crack: the effects of dose and routes of administration in abuse liability. Psychiatr Annals 1988; 18:513–520

Perez-Reyes M, DiGuiseppi S, Ondrusek G, Jeffcoat AR, Cook CE: Free-base cocaine smoking. Clin Pharmacol Ther 1982; 32:459–465

Ding Y-S, Fowler JS, Volkow ND, Gatley SJ, Logan J, Dewey S, Alexoff D, Wolf AP: Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse 1994; 18:152–160

Johanson CE, Shuster CR: A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther 1975; 193:676–688

Bergman J, Madras B, Johnson SE, Spealman RD: Effects of cocaine and related drugs in nonhuman primates, III: self administration by squirrel monkeys. J Pharmacol Exp Ther 1989; 251:150–155

Volkow ND, Wang G-J, Fowler JS, Gatley SJ, Ding Y-S, Logan J, Dewey SL, Hitzemann R, Lieberman J: Relationship between psychostimulant induced high and dopamine transporter occupancy. Proc Natl Acad Sci USA 1996; 93:10388–10392

Volkow ND, Ding Y-S, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey SL, Ashby C, Lieberman J R Hitzemann, Wolf AP: Is methylphenidate like cocaine? studies on their pharmaco­kinetics and distribution in human brain. Arch Gen Psychiatry 1995; 52:456–463

Chait LD: Reinforcing and subjective effects of methylphenidate in humans. Behavioral Pharmacology 1994; 5:281–288

Fowler JS, Volkow ND, Logan J, Gatley SJ, Pappas N, King P, Ding Y-S, Wang GJ: Comparison of [11C]cocaine and [11C]d-threo-methylphenidate for estimating dopamine transporter occupancy by cocaine in vivo. Synapse 1998; 28:111–116

Fischman MW, Foltin RW: Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991; 86:1563–1570